PRESENTATIONS

Odonate Corporate Presentation December 2020

Odonate Virtual Investor and Analyst Event December 2020

Results from CONTESSA: A Phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane – Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS)

Activity of Tesetaxel, an Oral Taxane, Given as a Single-agent in Patients with HER2-, Hormone Receptor + (HR+) Metastatic Breast Cancer (MBC) in a Phase 2 Study – Presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

​

Contact Us          Careers          Privacy Notice          Terms of Use

​

© 2020 Odonate Therapeutics, Inc.

​

​